Nuvectis Pharma, Inc. (NVCT)
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Ron Bentsur M.B.A.
|
Co-Founder, Chairman, CEO & President | 1.19M | -- | 1966 |
|
Dr. Enrique Poradosu Ph.D.
|
Co-Founder, Executive VP, Chief Scientific & Business Officer | 749.24k | -- | 1967 |
|
Mr. Shay Shemesh
|
Co-Founder, Executive VP, Chief Development & Operations Officer | 749.24k | -- | 1984 |
|
Mr. Michael Carson CPA
|
Vice President of Finance | -- | -- | 1976 |
Nuvectis Pharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 16
Description
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Corporate Governance
Upcoming Events
November 3, 2026 at 1:30 PM UTC
Nuvectis Pharma, Inc. Earnings Date
